Anika Therapeutics, Inc.
NASDAQ:ANIKMedical - Devices
-$0.06 today
- Market cap
- $182.44M
- Beta
- 0.23
- P/E (TTM)
- -17.3
- EPS (TTM)
- -$0.82
Volume 0.12M
Average 0.11M
ANIK Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Anika Therapeutics, Inc.NASDAQ: ANIK
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $17.77M rose 37.7% year over year, ahead of the +26.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 47.1% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.
Context
- Selling, general & admin amounted to 43.5% of revenue in FY2025, down 2.8 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $57.51M (+17.2%) for the fiscal year ending Dec 2026, a step up from the -11.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $17.77M+47.1% QoQ
- Last fiscal yearDec 2025
- $49.09M-11.6% YoY
- LTMMar 2026
- $53.95M+26.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 49.09M USD
- Year-over-year change
- -11.6%
- 4-year CAGR
- -9.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.09M | -11.6% |
| FY2024 | 2024-12-31 | 55.56M | -7.3% |
| FY2023 | 2023-12-31 | 59.93M | +17.0% |
| FY2022 | 2022-12-31 | 51.23M | -30.9% |
| FY2021 | 2021-12-31 | 74.1M | — |
Selling, General & Admin vs competitors
How ANIK compares with its peers on the latest reported figures
- ANIK's LTM Mar 2026 selling, general & admin of $53.95M is the 2nd highest of the 9 companies compared; the peer median is $36.9M.
- Its year-over-year change of +26.2% is the 3rd highest of 9, against a peer median of +3.2%.
- Selling, general & admin amounts to 46.4% of revenue for ANIK, versus a peer median of 108.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.08B | +51937.5% | +914.5% | 391112.6% | |
| LTM Mar 2026 | $53.95M | +26.2% | -1.4% | 46.4% | |
| LTM Mar 2026 | $50.4M | -0.9% | -15.8% | 47.1% | |
| LTM Mar 2026 | $42.18M | -24.8% | +1.9% | 130.7% | |
| LTM Mar 2026 | $37.26M | +7.2% | -5.9% | 108.4% | |
| LTM Mar 2026 | $36.54M | +18.5% | +18.5% | 63.3% | |
| LTM Mar 2026 | $31.78M | -9.7% | -9.1% | 56.8% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $15.75M | +155.8% | +17.1% | 850.8% |
| LTM Apr 2026 | $6.12M | -10.9% | -2.6% | — | |
| Peer median (excluding ANIK) | $36.9M | +3.2% | -0.4% | 108.4% | |
Competitors are the stored peer set for ANIK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 147.79M | 113.83M | 120.79M | 119.91M | 112.82M |
| Cost of Revenue | 64.85M | 40.61M | 38.26M | 43.91M | 49.01M |
| Gross Profit | 82.94M | 73.22M | 82.53M | 76M | 63.81M |
| Gross Margin | 56.1% | 64.3% | 68.3% | 63.4% | 56.6% |
| Research & Development | 27.33M | 18.32M | 21.76M | 25.54M | 25.77M |
| Selling, General & Admin | 74.1M | 51.23M | 59.93M | 55.56M | 49.09M |
| Operating Expenses | 80.33M | 69.55M | 81.69M | 81.1M | 74.86M |
| Depreciation & Amortization | 14.32M | 14.49M | 14.22M | 8.12M | 5.73M |
| EBITDA | (4.16M) | 18.81M | 17.37M | 5.36M | (3.58M) |
| EBITDA Margin | -2.8% | 16.5% | 14.4% | 4.5% | -3.2% |
| Operating Income | 2.62M | 3.67M | 844K | (5.1M) | (11.05M) |
| Operating Margin | 1.8% | 3.2% | 0.7% | -4.3% | -9.8% |
| Interest Income | — | 654K | 2.31M | — | 0 |
| Interest Expense | — | 0 | 0 | — | 0 |
| Other Income / Expenses | (188K) | 654K | 2.31M | 2.34M | 1.74M |
| Income Before Tax | 2.43M | 4.32M | 3.16M | (2.76M) | (9.31M) |
| Pre-Tax Margin | 1.6% | 3.8% | 2.6% | -2.3% | -8.2% |
| Income Tax Expense | (1.71M) | 2.12M | 6.6M | 6.06M | 672K |
| Net Income | 4.13M | (14.86M) | (82.67M) | (56.39M) | (10.88M) |
| Net Margin | 2.8% | -13.1% | -68.4% | -47.0% | -9.6% |
| EPS (Basic) | 0.29 | (1.02) | (5.64) | (3.83) | (0.76) |
| EPS (Diluted) | 0.28 | (1.02) | (5.64) | (3.83) | (0.76) |
| Weighted Avg Shares | 14.4M | 14.56M | 14.66M | 14.72M | 14.34M |
| Weighted Avg Shares (Diluted) | 14.63M | 14.56M | 14.66M | 14.72M | 14.34M |
Anika Therapeutics, Inc.
NASDAQ:ANIK
Intrinsic Alpha fair value
Locked
Current Price
$13.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.